

To,
Head, Listing Compliance Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.
Scrip Code: 542650

To,
Head, Listing Compliance Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block,
Bandra – Kurla Complex, Bandra (East),
Mumbai – 400051
Scrip Symbol: METROPOLIS

Sub: Intimation of Press Release

Dear Sir/ Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is the Press Release as mentioned below:

Mr. Surendran Chemmenkotil to join as the Chief Executive Officer (CEO) of Metropolis Healthcare Limited.

You are requested to take the above information on record.

Thanking you,

Yours faithfully

For **Metropolis Healthcare Limited**

Simmi Singh Bisht
Head – Legal and Secretarial
Membership No. A23360

Encl. a/a

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered & Corporate Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.



Press Release

Mr. Surendran Chemmenkotil to join as the Chief Executive Officer (CEO) of Metropolis Healthcare Limited.

India, Mumbai, December 9, 2022:

Mr. Surendran Chemmenkotil to join as the **Chief Executive Officer** of Metropolis Healthcare Limited. He is a seasoned leader with 34 years of rich and diverse experience across consumer facing companies such as Xerox India Limited and Bharti Airtel Limited. Mr. Surendran will be joining Metropolis after a robust and successful stint as Managing Director & Chief Executive Officer (CEO) of Airtel Networks Ltd, Nigeria, a leading telecommunications company in Nigeria. He comes with a vast experience across geographies, functions and businesses to his credit.

Mr. Surendran began his career as a Customer Engineer at Xerox India Limited and was elevated to the rank of the Head of Outsource and Customer Satisfaction at national level. He then joined Bharti Airtel Limited., in 2003 and has worked across several verticals and in different roles across the country. He was the CEO for Airtel Northeast & Assam Circle and then moved in as CEO for Karnataka circle, which is Airtel's flagship market, heading Mobile, Broadband and Enterprise lines of business between 2013-2015.

With this stellar and consistent performance in various roles across geographies within India, Mr. Surendran was selected as the Managing Director & CEO for Airtel Networks, Nigeria which is the biggest market for Airtel Africa.

Mr. Surendran will be joining Metropolis Healthcare Limited as CEO, effective from 2nd January 2023. We believe his rigorous execution skills, keen ability to build strong teams and skill in building consumer services businesses will be critical in building Metropolis 3.0 as a strong and a preferred consumer brand.

On the education front, Mr. Surendran holds a Bachelor of Engineering with specialisation in Electronics and Power from Regional Engineering College, Nagpur and MBA from Annamalai University.

*"In line with the strategy to build Metropolis as a strong consumer healthcare brand, we are delighted to onboard the **New CEO Mr. Surendran Chemmenkotil**. Metropolis has been built on a strong foundation of accuracy, ethics and empathy and has a strong vision for the future as a tech ready consumer brand, and I believe that Surendran is the right candidate to deliver the next phase of growth and ensure sustainable value creation for stakeholders. With over three and a half decades of experience, he will be instrumental in helping us cement our leadership position across our core markets and increase our market share & brand positioning across*

geographies for Metropolis. The board and I warmly welcome Surendran as the CEO and part of leadership team of Metropolis and wish him good luck in partnering with me to drive the Metropolis 3.0 strategy” - **Ameera Shah, Managing Director, Metropolis Healthcare Limited.**

“I am extremely pleased to be associated with Metropolis, a company that has been built on strong values, capabilities, and market leadership across markets. I am excited to build on Metropolis’s strong foundation of being a respected healthcare brand trusted by clinicians and patients. I am hopeful of furthering the strength of the Metropolis Brand with all stakeholders.”
– **Surendran Chemmenkotil**

About Metropolis: Established in 1981, Metropolis Healthcare Limited is a leading diagnostics company in India with a widespread presence in 20 states & 220 cities. Internationally, the company has presence in South Asia, Africa, and the Middle East. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company is empowered with a robust network of over 172 labs, 3379 collection centres and 10000+ touch points. Metropolis’ commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade, which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#)

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company: Metropolis Healthcare Ltd.

CIN -L73100MH2000PLC192798

Mr. Jeyasingh Balakrishnan – Head - Corporate Communications

jeyasingh.b@metropolisindia.com

www.metropolisindia.com

Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Sagar Shroff

+91 77383 77756 / +91 98205 19303

shogun.jain@sgapl.net / sagar.shroff@sgapl.net